Progressive Supranuclear Palsy Market Summary

• Progressive Supranuclear Palsy, also known as Steele-Richardson-Olszewski and Parkinson-plus syndrome, is a rare neurodegenerative disorder and the most common atypical Parkinsonism. 
• As per secondary searches, Progressive Supranuclear Palsy is more common in men in comparison to women.

Progressive Supranuclear Palsy Market & Epidemiology Analysis

• Approximately one in every 100,000 individuals over the age of 60 is affected by Progressive Supranuclear Palsy.
• PSP comprises several phenotype variants; Richardson’s syndrome is the most common phenotype of PSP. Other phenotypes include PSP-Parkinsonism, PSP with a predominant frontal presentation, and PSP with a corticobasal syndrome, and others.
• The most frequent comorbidities observed in Progressive Supranuclear Palsy Patients are nervous system disorders, connective tissue diseases, eye disorders, and non-traumatic joint disorders.
• Currently, there is no FDA approved therapies for the treatment of progressive supranuclear palsy. However medications such as levodopa, amantadine, ropinirole, hypnotics, anxiolytics, botulinum toxin, and other can be used to manage symptoms. 
• The emerging Progressive Supranuclear Palsy Pipeline includes AZP2006 (AlzProtect), AMX0035 (Amylyx Pharmaceuticals), TPN-101 (Transposon Therapeutics), FNP-223 (Ferrer), and others.
• In June 2025, Ferrer announced that the US FDA has granted the Fast Track designation to FNP-223 for treatment of patients with Progressive Supranuclear Palsy.
• In April 2025, AlzProtect’s AZP2006 was chosen as one of the initial two therapies to be tested in the newly launched national Phase II Platform Trial for Progressive Supranuclear Palsy in the United States. Funded by the National Institute on Aging (NIH), the trial aims to fast-track the development of effective treatments for PSP.
• In May 2024, Transposon Therapeutics announced that the US FDA has granted the Fast Track designation to TPN-101 for treatment of patients with Progressive Supranuclear Palsy, based on positive results from a Phase II clinical trial.

Request for Unlocking the Sample Page of the "Progressive Supranuclear Palsy Treatment Market"

Key Factors Driving the Progressive Supranuclear Palsy Market

• Rising Progressive Supranuclear Palsy Prevalence

Increasing awareness, improved diagnostic tools, and better recognition of atypical parkinsonian disorders are contributing to a growing diagnosed patient pool, strengthening market demand.

• Advancements in PSP Diagnosis

Enhanced imaging technologies, biomarker exploration, and refined clinical criteria are enabling earlier identification, pushing the need for targeted therapies.

• High Unmet Medical Needs

With no curative therapies and limited symptomatic treatment options available, there is a significant unmet need that drives R&D focus and commercial interest.

• Growing Pipeline of Therapeutic Candidates

Multiple emerging therapies targeting tau pathology and neurodegeneration are under development, generating optimism for disease-modifying options.

• Expanding Awareness Initiatives

Educational campaigns and patient support programs are improving disease literacy among clinicians and patients, driving timely diagnosis and treatment adoption.

• Improved Understanding of Tauopathies

Scientific advancements in understanding tau-related neurodegeneration are opening new therapeutic pathways, fostering innovation in PSP treatment strategies.

DelveInsight's “Progressive Supranuclear Palsy Treatment Market Insight, Epidemiology and Market Forecast – 2040” report delivers an in-depth analysis of progressive supranuclear palsy epidemiology, market, and clinical development in PSP. In addition to this, the report provides historical and forecasted epidemiology and market data as well as a detailed analysis of the PSP market trends in the United States, EU4 (Germany, France, Italy, and Spain ), the United Kingdom, and Japan.

Progressive Supranuclear Palsy Treatment Market Report provides real-world prescription pattern analysis, emerging drugs assessment, market share, and uptake/adoption pattern of individual therapies, as well as historical and forecasted progressive supranuclear palsy market size from 2020 to 2040 in 7MM. The report also covers current Kaposi sarcoma treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Progressive Supranuclear Palsy Understanding and Treatment Algorithm

Progressive Supranuclear Palsy Overview 

Progressive Supranuclear Palsy, also known as Steele-Richardson-Olszewski syndrome or a Parkinson-plus syndrome, is a rare and serious neurodegenerative disorder that characterized by a gradual decline in motor, cognitive, and behavioural functions. It is the most common form of atypical Parkinsonism and falls under a group of conditions referred to as tauopathies due to the abnormal accumulation of the tau protein in the brain. This accumulation primarily affects regions such as the basal ganglia and brainstem, resulting in the formation of tau tangles that lead to the degeneration of brain cells. The exact cause of PSP remains unknown.

PSP typically affects the individuals over age of 60 years, with symptoms gradually worsening over time. One of the earliest and most distinctive symptoms is difficulty with balance and frequent unexplained falls, often occurring backward. As the disease progresses, individuals develop increasing problems with eye movements (especially looking up or down), blurred or double vision, difficulty in speaking and swallowing, stiffness, and others. 

There are several subtypes of PSP however, PSP-Parkinsonism, closely resembles classic Parkinson’s disease and presents with symptoms such as bradykinesia (slowed movement), muscle rigidity, and tremors. Other recognized subtypes include PSP with predominant frontal lobe symptoms, Richardson’s syndrome, PSP-corticobasal syndrome, and pure akinesia with gait freezing.

Progressive Supranuclear Palsy Diagnosis

The diagnosis of progressive supranuclear palsy can be challenging, as its symptoms significantly overlap with other movement disorders, such as Parkinson’s disease, frontotemporal dementia, and corticobasal degeneration. There is no specific test that can confirm PSP, so diagnosis is typically based on a combination of characteristic clinical symptoms, through a neurological examination, and the exclusion of other possible conditions. Imaging studies like MRI may support the diagnosis by showing specific patterns of brain atrophy.

Currently, two main diagnostic criteria are commonly used to identify progressive supranuclear palsy: the MDS-PSP and NINDS-SPSP criteria. The MDS-PSP criteria incorporate a range of clinical signs and supportive features designed to distinguish PSP from similar conditions and aid in making an earlier and more accurate diagnosis.

Further details related to country-based variations in diagnosis are provided in the report

Progressive Supranuclear Palsy Treatment

Currently, there are no approved drugs or standardized clinical guidelines specifically for the treatment of progressive supranuclear palsy. The treatment primarily aims to manage symptoms, offer supportive care, and improve the patient's quality of life. Medications commonly used in Parkinson’s disease, such as levodopa, may help alleviate some motor symptoms like rigidity, tremors, and bradykinesia, but the response in PSP is typically limited and short-lived. Dopamine agonists such as amantadine and ropinirole may be used alone or alongside levodopa, though with similarly modest benefits. 

In addition to medication, a multidisciplinary approach is essential. Physical therapy helps improve mobility and balance, occupational therapy supports daily functioning, and speech and swallowing therapy addresses communication and feeding difficulties. These comprehensive supportive measures are essential in maintaining the highest possible quality of life for individuals with PSP.

Progressive Supranuclear Palsy Epidemiology

The Progressive Supranuclear Palsy epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as total prevalent cases of PSP, total diagnosed prevalent cases of PSP, gender-specific diagnosed prevalent cases of PSP, phenotype-specific diagnosed prevalent cases of PSP, comorbidity associated cases with PSP in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034. 

• Among the 7MM, the United States has captured the highest number of Progressive Supranuclear Palsy Diagnosed Prevalent Cases in 2024.
• Among all the phenotype specific cases of PSP, Richardson’s syndrome accounted for more than 50% of cases in 2024.
• As per the analysis, PSP is more prevalent in males than in females, with approximately 60% of the cases occurred in males in 2024.
• In 2024, among all the comorbidities associated cases with PSP, nervous system disorders had the highest cases in Japan.

Progressive Supranuclear Palsy Drug Analysis

The drug chapter segment of Progressive Supranuclear Palsy Therapeutics Market Report encloses a detailed analysis of PSP-marketed drugs and emerging Progressive Supranuclear Palsy Pipeline Drugs. It also deep dives into PSP’s pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations. 

Progressive Supranuclear Palsy Emerging Drugs

• AZP2006 (ezeprogind): AlzProtect

AZP2006 is an orally available small molecule with a novel mechanism of action and effects. It involves the action of a neurotrophic factor, which combines reinforced neuroprotective efficacy and anti-neuroinflammation activity. It has exceptional therapeutic potential to treat the physiopathological causes of progressive supranuclear palsy and other related tauopathies such as Alzheimer’s disease. 

In September 2024, the company announced the completion of Phase IIa clinical trial of AZP2006 for the treatment of PSP. In a 3-month Phase IIa study in PSP patients, AZP2006 demonstrated encouraging clinical and biomarker signals of efficacy. These positive outcomes were further supported by results from a 6-month open-label extension study, reinforcing its therapeutic potential. The compound has received Orphan Drug Designation from both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

In April 2025, The Progressive Supranuclear Palsy Trial Platform (PTP), led by Drs. Adam Boxer (University of California, San Francisco [UCSF]), Irene Litvan (University of California, San Diego), Julio Rojas (UCSF) and Anne-Marie Wills (Massachusetts General Hospital), selected two promising drug candidates—Axon Neuroscience’s AADvac1 and Alzprotect’s AZP2006—for inclusion in the platform trial as the first two compounds to be evaluated. The trial aims to accelerate the development of effective treatments for PSP, a rare and fatal neurodegenerative disease.

• AMX0035: Amylyx Pharmaceuticals

AMX0035 is an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol (known as ursodoxicoltaurine). AMX0035 has a strong scientific rationale in PSP, targeting key upstream pathways in disease pathophysiology including the unfolded protein response and mitochondrial dysfunction. Further, the drug has been shown to reduce p-tau in Alzheimer’s disease trial. 

AMX0035 is currently being investigated in a global Phase IIb/III (ORION) clinical trial designed to assess the efficacy, safety, and tolerability in people living with PSP. The trial is anticipated to complete by April 2026. Amylyx Pharmaceuticals expect safety and efficacy data from an unblinded analysis of the Phase IIb portion of the Phase IIb/III ORION clinical trial in Q3 2025.

Note: Detailed emerging therapies assessment will be provided in the final report.

Progressive Supranuclear Palsy Drug Class Insights

• Tau protein Inhibitor 

In Progressive Supranuclear Palsy, monoclonal antibodies offer a promising immunotherapeutic strategy by targeting abnormal tau protein, aiming to neutralize it, prevent its spread between brain cells, and slow the progression of the disease

• O-GlcNAcase (OGA) Inhibitor

O-GlcNAcase (OGA) inhibitors are a class of drugs that work by blocking the enzyme O-GlcNAcase, which is responsible for removing a sugar molecule called O-GlcNAc from proteins. Inhibiting this enzyme increases O-GlcNAc levels on proteins, influencing their function and stability. In Progressive Supranuclear Palsy, OGA inhibitors represent a promising therapeutic approach by increasing the O-GlcNAcylation of tau protein, which promotes its stabilization in a non-toxic state and reduces pathological aggregation. This mechanism may slow disease progression and serve as a disease-modifying treatment in PSP, where effective therapies are currently lacking. Early research has shown encouraging results in terms of safety and potential clinical benefit.

Progressive Supranuclear Palsy Market Outlook

There is currently no cure for PSP, and existing treatments focus solely on managing symptoms. The Progressive Supranuclear Palsy Treatment Market Landscape lacks both disease-modifying therapies and standardized guidelines. Although symptomatic treatments are commonly used, they generally offer only mild to moderate relief. Since no single medication can effectively treat all the symptoms of PSP, using targeted therapies for individual symptoms may offer greater benefits.

Patients with progressive supranuclear palsy are often prescribed antiparkinsonian medications such as levodopa and amantadine to help improve balance and muscle flexibility. Additionally, Selective Serotonin Reuptake Inhibitors (SSRIs) and other antidepressants are commonly used to manage depression and mood-related symptoms associated with the condition. Other medications, including hypnotics, anxiolytics, botulinum toxin, anti-inflammatory drugs, and antiepileptics, may also be used to address a range of symptoms related to PSP. 

Further, the pipeline for Progressive Supranuclear Palsy Treatment, including AMX0035 (Amylyx Pharmaceuticals), AZP2006 (AlzProtect), TPN-101 (Transposon Therapeutics), FNP-223/ ASN90 (Ferrer/ Asceneuron), and Bepranemab (UCB0107) (UCB Biopharma), have the potential to significantly transform the progressive supranuclear palsy treatment landscape and market dynamics in the coming years.

Progressive Supranuclear Palsy Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2025–2040. The landscape of progressive supranuclear palsy treatment has experienced a profound transformation with the uptake of novel medicines. These innovative therapies are redefining standards of care. 

Progressive Supranuclear Palsy Pipeline Development Activities

The Progressive Supranuclear Palsy Therapeutics Market Report provides insights into different therapeutic candidates in the marketed and emerging stages. It also analyses key Progressive Supranuclear Palsy Companies involved in developing targeted therapeutics. The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for PSP therapies. 

Latest KOL Views on Progressive Supranuclear Palsy

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Professors, and Others.

DelveInsight’s analysts connected with 15+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as University of Pisa, University of Tokyo School of Medicine, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or progressive supranuclear palsy market trends. 

Progressive Supranuclear Palsy Qualitative Analysis

We perform qualitative and Progressive Supranuclear Palsy Market Intelligence analysis using various approaches, such as SWOT and conjoint analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, designation, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy. The analyst analyzes multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry.

In efficacy, the trial’s primary and secondary outcome measures are evaluated. Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials.

Progressive Supranuclear Palsy Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and a payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs, including Medicare, Medicaid, Health Insurance Program (CHIP), and the state and federal health insurance marketplaces, are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs) and third-party organizations that provide services and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Progressive Supranuclear Palsy Market Report Scope

• The Progressive Supranuclear Palsy Therapeutics Market Report covers a segment of key events, an executive summary, a descriptive overview, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the PSP market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Progressive Supranuclear Palsy Therapeutics Market Report provides an edge while developing business strategies, by understanding trends, through SWOT and conjoint analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Progressive Supranuclear Palsy Drugs Market.

Progressive Supranuclear Palsy Market Report Insights

• Patient-based Progressive Supranuclear Palsy Market Forecasting
• Therapeutic Approaches
• Progressive Supranuclear Palsy Pipeline Analysis
• Progressive Supranuclear Palsy Market Size and Trends
• Existing and Future Market Opportunity 

Progressive Supranuclear Palsy Market Report Key Strengths

• 16 -Year Progressive Supranuclear Palsy Market Forecast
• 7MM Coverage 
• PSP Epidemiology Segmentation
• Key Cross Competition 
• Conjoint analysis
• Progressive Supranuclear Palsy Drugs Uptake
• Key Progressive Supranuclear Palsy Market Forecast Assumptions

Progressive Supranuclear Palsy Market Report Assessment

• Current Progressive Supranuclear Palsy Treatment Practices
• Progressive Supranuclear Palsy Unmet Needs
• Progressive Supranuclear Palsy Pipeline Drugs Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint)

Key Questions Answered in the Progressive Supranuclear Palsy Market Report

• What was the Progressive Supranuclear Palsy Market Size, the market size by therapies, market share (%) distribution in 2020, and what would it look like in 2040? What are the contributing factors for this growth?
• At what CAGR, Progressive Supranuclear Palsy Drugs Market is expected to grow at the 7MM level during the study period (2020–2040)?
• How is Japan's PSP competitive landscape evolving? 
• How will upcoming emerging therapies are going to impact MEPACT’s market share?

• What are the disease risks, burdens, and Progressive Supranuclear Palsy Unmet Needs? 
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to PSP?
• What is the historical and forecasted PSP patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• What factors are affecting the increase in the diagnosis of symptomatic cases?

• What are the current options for the treatment of PSP? What are the current treatment guidelines for the treatment of PSP in the US and Europe?
• How many companies are developing therapies for the treatment of PSP?
• Which key designations have been granted for the emerging therapies for PSP?
• What is the cost burden of approved therapies on the patient?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.

Reasons to Buy the Progressive Supranuclear Palsy Market Report

• The Progressive Supranuclear Palsy Therapeutics Market Report will help in developing business strategies by understanding the latest trends and changing treatment dynamics and driving factor for Progressive Supranuclear Palsy Drugs Market.
• Insights on patient share/disease burden, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying upcoming players in the Progressive Supranuclear Palsy Drugs Market will help devise strategies to help get ahead of competitors.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand KOLs’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Progressive Supranuclear Palsy Drugs Market so that the upcoming players can strengthen their development and launch strategy

Stay updated with us for Recent Articles 

• Progressive Supranuclear Palsy– A neurodegenerative disorder
• Progressive Supranuclear Palsy Market Infographic
• Progressive Supranuclear Palsy Newsletter
• New DelveInsight Blogs